The first and only FDA-approved topical gel for facial angiofibroma associated with tuberous sclerosis in adults and children 6 years and older
HYFTOR™ is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients 6 years of age and older. Facial angiofibroma is one of the most visible manifestations of TSC.1,2
Learn more about the impact TSC and facial angiofibroma can have on your patients.
See the latest support, resources, and downloads.
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR.
WARNINGS AND PRECAUTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.